Asad Haider, an analyst from Goldman Sachs, maintained the Buy rating on Eli Lilly & Co. The associated price target remains the same with $1,260.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Asad Haider has given his Buy rating due to a combination of factors tied to Eli Lilly’s execution in obesity and its broader strategic agenda. Following meetings with senior management, he concluded that 2026 revenue guidance appears deliberately conservative, underpinned by strong recent trends, particularly in ex-U.S. demand for Mounjaro, which makes the lower end of the range look well supported.
Haider also highlights management’s confidence in the upcoming orforglipron launch and its expected ramp in the second half of 2026, alongside a robust pipeline where most assets are unrelated to weight loss, reducing concentration risk. In addition, a more flexible approach to capital deployment, including potential later-stage business development, partnerships such as in oral PCSK9, and even sizeable buybacks, supports a favorable risk‑reward, especially as Lilly’s leadership in obesity appears resilient against emerging competitors like Novo Nordisk.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $1,500.00 price target.